SECsense Logo

Arbutus Biopharma 8-K Report: Key Event Insights from January 13, 2025

$ABUS
Form 8-K
Filed on: 2025-01-13
Source
Arbutus Biopharma 8-K Report: Key Event Insights from January 13, 2025

Based on the provided XML snippet, here are the key pieces of information extracted from the financial report:

  1. Filing Type: This is an 8-K form, which is typically used to report significant events that shareholders should know about.
  2. Company Information:
  • Name: Arbutus Biopharma Corporation
  • CIK (Central Index Key): 0001447028
  • IRS Employer Identification Number: 98-0597776
  • Address: 701 Veterans Circle, Warminster, PA 18974
  • Phone Number: 267-469-0914
  • Ticker Symbol: ABUS (listed on NASDAQ)
  1. Reporting Period: The report covers a specific date:
  • Date of Event: January 13, 2025
  1. Shares Information:
  • Type of Shares: Common Shares, without par value.
  • Unit of Measurement: The financial data is reported in USD (U.S. Dollars) and shares.
  1. Schema Reference: The report refers to a specific schema (gnw-20190101.xsd), which indicates the structure of the filing.

Insights:

  • The filing indicates that Arbutus Biopharma Corporation is reporting on an event that occurred on January 13, 2025. It’s essential to look for additional details in the complete report to understand the nature of the event and its potential impact on the company's financial position or operations.
  • The absence of any immediate financial metrics or performance indicators in this segment suggests that the main focus may be on a significant corporate event rather than routine financial performance.
  • As a publicly traded company, any major developments disclosed in the 8-K could affect stock performance and investor sentiment, making this filing particularly relevant for current and prospective investors.

For a thorough analysis, it is advisable to review the entire 8-K document for context regarding the event being reported.